|Bid||0.0000 x 1200|
|Ask||0.0000 x 1200|
|Day's Range||0.8300 - 0.9100|
|52 Week Range||0.6200 - 11.1800|
|Beta (5Y Monthly)||1.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 24, 2022 - Aug 29, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.25|
Subscribe to Yahoo Finance Plus to view Fair Value for RDHL
The drugmaker is cutting one-third of its U.S. commercial workforce as part of a plan to save $50 million. The move comes as the biotech industry sees cuts across the board as the highs of the pandemic fade away.
View more earnings on RDHLSee more from BenzingaThe Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows PromiseDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its first quarter 2022 financial results and operational highlights, targeting positive cash from operations1 to start during H2/22 and recent implementation of a comprehensive cost reduction plan, expected to generate operational cost savings of approximately $50 million over the next 18 months.